Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.68 |
| ▸ | CPB1 | P15086 | 1/20 | 0.61 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720591 | 0.91 | HSD11B1 (0.84) | MGLLKMT2AMEN1HSD11B1SLC18A3 | |
| SCHEMBL5476619 | 0.91 | HSD11B1 (0.84) | MGLLKMT2AMEN1HSD11B1SLC18A3 | |
| SCHEMBL1720091 | 0.91 | MGLL (0.84) | MGLLKMT2AMEN1HSD11B1 | |
| SCHEMBL5479680 | 0.90 | ALDH1A1 (0.62) | MGLLKMT2AMEN1HSD11B1ALDH1A1 | |
| SCHEMBL1720183 | 0.90 | MGLL (0.82) | MGLLKMT2AMEN1HSD11B1CPB1 | |
| SCHEMBL968362 | 0.88 | CPB1 (0.59) | MGLLKMT2AMEN1HSD11B1CPB1 | |
| SCHEMBL21848101 | 0.88 | CPB1 (0.59) | MGLLKMT2AMEN1HSD11B1CPB1 | |
| SCHEMBL16695294 | 0.88 | ACHE (0.60) | MGLLKMT2AMEN1HSD11B1ACHE | |
| SCHEMBL3284280 | 0.85 | SMN1; SMN2 (0.68) | MGLLKMT2AMEN1HSD11B1ACHE | |
| SCHEMBL16695142 | 0.85 | SMN1; SMN2 (0.68) | MGLLKMT2AMEN1HSD11B1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | MGLL 3022/4885KMT2A 1063/4885MEN1 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.